Robbins Shira L, Wang Jeffrey W, Frazer Jeffrey R, Greenberg Mark
Viterbi Family Department of Ophthalmology, University of California, San Diego; Ratner Children's Eye Center at the Shiley Eye Institute, University of California, San Diego.
Viterbi Family Department of Ophthalmology, University of California, San Diego.
J AAPOS. 2019 Aug;23(4):193-199. doi: 10.1016/j.jaapos.2018.12.008. Epub 2019 Apr 11.
An increasing number of surgical strabismus patients are taking oral anticoagulant and antiplatelet agents, with more diverse mechanisms of action than those used in the past. The decision as to whether to continue these drugs throughout the perioperative period is difficult and must be based on the balance between hemorrhagic and thrombotic risk. To help guide strabismus surgeons with clinical management in these cases, we review potential hemorrhagic complications of strabismus surgery and examine the use of anticoagulant and antiplatelet drugs during the perioperative period. Surgical strategies that might help minimize intraoperative hemorrhage in patients on anticoagulant therapy are also discussed.
越来越多的斜视手术患者正在服用口服抗凝剂和抗血小板药物，其作用机制比过去使用的药物更加多样。决定是否在围手术期全程继续使用这些药物是困难的，必须基于出血风险和血栓形成风险之间的平衡。为了帮助指导斜视外科医生对这些病例进行临床管理，我们回顾了斜视手术潜在的出血并发症，并研究了围手术期抗凝剂和抗血小板药物的使用情况。还讨论了可能有助于减少接受抗凝治疗患者术中出血的手术策略。
